Patent Search

Invention Title	SAXAGLIPTIN NANOMICELLES FOR NEURODEGENERATIVE DISORDERS
Publication Number	35/2021
Publication Date	27/08/2021
Publication Type	INA
Application Number	201911034433
Application Filing Date	27/08/2019
Priority Number	
Priority Country	
Priority Date	
Field Of Invention	CHEMICAL
Classification (IPC)	A61K0009107000, A61K0009000000, A61K0009510000, A61K0031337000, A61K0047340000

Inventor

Name	Address	Country	Nation
BHAVNA	11/107 DR. AMBEDKAR NAGAR SECTOR-6 NEW DELHI-110062, INDIA	India	India
DEEPIKA SHARMA	VILLA-A-06, PANACHE VALLEY, NEAR USHA COLONY SAHASTRADHARA ROAD, DEHRADUN-248013, U.K, INDIA	India	India

Applicant

Name	Address	Country	Nationa
BHAVNA	School of Pharmaceutical and Population Health Informatics, DIT University, Dehradun- 248009, India.	India	India

Abstract:

The present invention relates to a novel formulation for treating neurodegenerative disorders, more particularly the present invention relates to drug loaded polymeric nanomicelle for ocular to brain delivery/ocular administration comprising, a polymeric drug carrier nanomicelle, a drug encapsulated within the polymer core of said polyr carrier nanomicelles and a surfactant.

Complete Specification

[0001] The present invention relates to a novel formulation for treating neurodegenerative disorders, more particularly the present invention relates to nanoformulatior Saxagliptin (DPP-4 inhibitor) loaded polymeric nanomicelles, optionally in combination with one or more other inactive agents, for treatment of neurodegenerative disorders, by ocular to brain route of drug delivery.

BACKGROUND OF THE INVENTION

[0001] Neurodegenerative disorders (progressive loss of structure and/or function of neurons) are usually characterized by accumulation of abnormal protein aggrega that leads to inflammation as well as oxidative stress in the central nervous system (CNS). Nearly, 1.5 billion of population suffer from brain disorders. Alzheimer's diseas (AD) is the commonest cause of dementia in ageing adults. Alzheimer's, Parkinson's, Huntington's, and other neurodegenerative disorders share many common features both cellular and subcellular levels. Intracellular and extracellular changes could be observed in neurodegenerative diseases. Alzheimer's disease (AD), the commonest cause of dementia in ageing adults, is characterized by gradual cognitive impairment and severe functional disability.

[0002] Alzheimer's disease (AD) should be regarded as a degenerative metabolic disease caused by brain insulin resistance and deficiency, and overlapping with the molecular, biochemical, pathophysiological, and metabolic dysfunctions in diabetes mellitus, non-alcoholic fatty liver disease, and metabolic syndrome.

View Application Status

Department of Industrial Policy and Promotion
Government of India

Page last updated on: 26/06/2019